



# Summary of investigation results

## Tramadol hydrochloride, Tramadol hydrochloride/acetaminophen

July 7, 2015

### Non-proprietary name

- a. and b. Tramadol hydrochloride
- c. Tramadol hydrochloride/acetaminophen

### Brand name (Marketing authorization holder)

- a. Tramal Injection 100 (Nippon Shinyaku Co., Ltd.)
- b. Tramal Capsules 25 mg and 50 mg, and Tramal OD Tablets 25 mg and 50 mg (Nippon Shinyaku Co., Ltd.)
- c. Tramcet Combination Tablets (Janssen Pharmaceutical K.K.)

### Indications

- a. Relief of pain for the following diseases and conditions  
Cancers with pain and postoperative pain after surgery
- b. Relief of pain in the following diseases that cannot be managed by treatment with non-opioid analgesics  
Cancers associated with pain and chronic pain
- c. Relief of pain in the following diseases that cannot be managed by treatment with non-opioid analgesics  
Non-cancerous chronic pain and pain after tooth extraction

### Summary of revision

'Respiratory depression' should be newly added to the Clinically significant adverse reactions section.



## **Background of the revision and investigation results**

At the time of approval of new extended release tablets of tramadol hydrochloride, 'Respiratory depression' has been described in the Clinically significant adverse reactions section of package insert. In addition, cases associated with respiratory depression have been reported in patients treated with tramadol hydrochloride or tramadol hydrochloride/acetaminophen in Japan. Following an investigation result based on the opinions of expert advisors and the available evidence, the MHLW/PMDA concluded that revision of the package insert was necessary.

## **The number of reported adverse reactions and fatal cases in the last 3 fiscal years in Japan**

- a. and b. A total of 4 cases associated with respiratory depression have been reported (including a case for which a causal relationship to the product could not be ruled out). Of the 4 cases, no fatality has been reported.
- b. A total of 6 cases associated with respiratory depression have been reported (including 4 cases for which a causal relationship to the product could not be ruled out; however, a case was for condition not included in the approved indications). Of the 6 cases, no fatality has been reported.